Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.
Artivion, Inc. (NYSE: AORT) is a medical device company focused on cardiac and vascular surgery, particularly the treatment of aortic diseases. News about Artivion frequently centers on its aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as clinical and regulatory developments related to these products.
Investors and clinicians following AORT news can expect regular updates on quarterly financial results, including revenue trends for key product lines such as stent grafts, On-X valves, BioGlue surgical sealant and preservation services. Earnings releases often discuss constant currency growth, adjusted EBITDA and non-GAAP performance metrics, along with management’s commentary on business momentum and financial outlook.
Artivion’s news flow also highlights progress in its aortic disease clinical programs. Recent announcements have covered the PERSEVERE and PROTECT trials for the AMDS Hybrid Prosthesis, including late-breaking data presented at major cardiothoracic surgery meetings, as well as the ARTIZEN pivotal trial evaluating the Arcevo LSA Hybrid Stent Graft System for acute and chronic aortic arch pathologies. These updates provide insight into the clinical performance and potential regulatory pathways for the company’s aortic technologies.
Additional news items may include participation in healthcare and medtech investor conferences, amendments to credit facilities, real estate transactions related to manufacturing capacity, and executive leadership changes disclosed through SEC filings and press releases. For market participants tracking AORT, this news page offers a centralized view of Artivion’s financial communications, clinical milestones and corporate developments over time.
Artivion (NYSE:AORT) will participate virtually in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference with a fireside chat on March 17, 2026 at 9:20 a.m. ET.
According to Artivion, the live webcast will be accessible on the company's Investors page and an archived copy will be available for 90 days.
Artivion (NYSE: AORT) reported strong Q4 and full-year 2025 results, with GAAP revenue $116.0M Q4 and $441.3M for 2025. Adjusted revenue was $118.3M Q4 and $443.6M FY (adjusted constant currency growth 18% Q4, 13% FY). GAAP net income was $2.4M Q4 and $9.8M FY; adjusted EBITDA was $22.7M Q4 and $89.6M FY. Company filed final PMA module for AMDS Hybrid Prothesis and reported positive IDE clinical data for Endospan NEXUS TRIOMPHE and AMDS PERSEVERE.
Artivion (NYSE: AORT) will present new clinical data at the 62nd Society of Thoracic Surgeons meeting showing favorable outcomes from two IDE trials. NEXUS TRIOMPHE (n=94) reported 94% survival from lesion-related death and 91% freedom from disabling stroke at 1 year. AMDS PERSEVERE (n=93) showed persistent aortic remodeling, zero distal anastomotic new entry tears through 2 years, and minimal additional morbidity.
Artivion (NYSE: AORT) will release fourth quarter 2025 financial results on Thursday, February 12, 2026 after market close.
The company will host a teleconference and live webcast at 4:30 p.m. ET with CEO Pat Mackin, followed by Q&A; replay will be available about one hour after the event. Earnings materials and the webcast/replay will be posted in the Investors section at www.artivion.com.
Artivion (NYSE: AORT) reported strong Q3 2025 results on Nov 6, 2025: revenue $113.4M (+18% GAAP; +16% non-GAAP constant currency vs Q3 2024) and net income $6.5M ($0.13/diluted). Adjusted EBITDA rose 39% to $24.6M. Commercial growth drivers included stent grafts +38% and On-X +25% (year-over-year).
Corporate updates: first patient enrolled in ARTIZEN IDE trial for Arcevo, favorable AMDS clinical data presented, and refinancing that extends credit maturity to 2031 plus a $150M delayed-draw term loan. Full-year 2025 guidance midpoints were raised for constant-currency revenue and adjusted EBITDA.
Artivion (NYSE: AORT) announced the first patient has been treated in the ARTIZEN pivotal trial evaluating the Arcevo LSA Hybrid Stent Graft System for acute and chronic aortic arch pathologies. The prospective, multicenter, non-randomized study will enroll 132 participants across up to 30 U.S. and European centers, with follow-up to five years and emphasis on 1-year outcomes. Primary combined safety and efficacy endpoints include all-cause mortality, new permanent disabling stroke, new permanent paraplegia/paraparesis, unanticipated aortic reoperation in the treated segment, and left subclavian artery occlusion. Artivion says the trial is intended to support a U.S. PMA submission and estimates an incremental $80 million U.S. market opportunity for Arcevo as soon as 2029.
Artivion (NYSE: AORT) will participate in the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at the Lotte New York Palace Hotel.
The company's fireside chat begins at 8:00 a.m. ET. A live webcast will be available on Artivion's Investors page at www.artivion.com, with an archived copy accessible for 90 days after the event.
Artivion (NYSE: AORT) will release third quarter 2025 financial results on Thursday, November 6, 2025 after market close, with a teleconference and live webcast at 4:30 p.m. ET.
Pat Mackin, Chairman, President and CEO, will host the call and Q&A. To join live, dial 201-689-8261 a few minutes before 4:30 p.m. ET. A replay will be available about one hour after the event via toll-free 877-660-6853 or 201-612-7415 using conference number 13755945. The live webcast and replay and the earnings press release with financial and statistical information will be accessible in the Investors section at www.artivion.com under Webcasts & Presentations.
Artivion (NYSE:AORT) presented late-breaking data from the AMDS PERSEVERE and PROTECT trials at the 39th EACTS Annual Meeting on October 13, 2025. The PERSEVERE 30-day analysis (n=40 with organ malperfusion) showed visceral malperfusion resolution in 83% and renal malperfusion resolution in 74%, with radiographic renal resolution in all affected patients. The PROTECT real-world registry (n=141) reported outcomes consistent with PERSEVERE and DARTS, including renal failure requiring dialysis 4.2%, unanticipated reoperation 1.4%, no paralysis/paraparesis, and 95.3–100% positive aortic remodeling in zones 1–3.
Artivion (NYSE:AORT), a cardiac and vascular surgery company specializing in aortic disease, announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company will engage in a fireside chat on September 10, 2025, at 2:35 pm ET at the Sheraton New York Times Square Hotel.
Investors can access the live webcast through Artivion's website at www.artivion.com in the Investors section. The webcast recording will remain available for 90 days following the presentation.